Client feedback, leading legal directory
They understand the science, the regulators and the financing markets, which is unusual in one team.
Client feedback, leading legal directory
Strong on antitrust analysis in a pharmaceutical acquisition with multiple overlaps.
Client feedback, leading legal directory
Exceptional on a complex licensing deal that involved three continents.
Client feedback, leading legal directory
They helped us through an FDA inquiry with a calm, well-organized approach.
Client feedback, leading legal directory
Superb on health data privacy, including HIPAA and state laws, for our digital health product.
Client feedback, leading legal directory
Their M&A team negotiated a tough earn-out structure with real creativity.
Client feedback, leading legal directory
They know how investors think about clinical risk and priced the deal language accordingly.
Client feedback, leading legal directory
A team that works well with our scientific founders and our board.
Client feedback, leading legal directory
They coordinated patent litigation strategy across the US and Europe with precision.
Client feedback, leading legal directory
Helpful and commercial on our IPO, from pre-filing to pricing.
Overview
Corvane Ryle offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet their needs. We act for biotechnology and pharmaceutical companies, medical device and diagnostics makers, digital health businesses, providers and payors, and the investors and lenders that finance them, including clients such as Arvelo Health and Meridian Arc Therapeutics.
Our work spans the full life cycle of a product and a company: early financing and collaboration agreements, clinical and regulatory strategy, licensing, IPOs and follow-on offerings, M&A, intellectual property and patent litigation, and ongoing compliance. Lawyers in New York, Washington, D.C., San Francisco, Boston, London, Brussels and Singapore work as one team.
The regulatory and policy environment is changing in ways that affect valuation and structure. Drug pricing reform under the Inflation Reduction Act, FDA guidance on AI-enabled devices and decision support, the EU Pharmaceutical Package, the European Health Data Space and the EU AI Act's treatment of medical AI all bear on strategy. HIPAA, state consumer health data laws such as Washington's My Health My Data Act, and FTC scrutiny of health apps reshape the privacy landscape for digital health. Antitrust agencies continue to review life sciences transactions and licensing carefully.